The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma

The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma

Five cases were treated by adding daily low-dose thalidomide (50 mg) to bortezomib and dexamethasone therapy for refractory multiple myeloma. This therapy was effective in four cases, with an improvement of bone pain and regression of M-protein. One case was treated with cyclophosphamide, thalidomid...

Full description

Bibliographic Details
Main Authors: Hashimoto, Shigeo, Kuroha, Takashi, Yano, Toshio, Sato, Naoko, Furukawa, Tatsuo
Format: Online
Language:English
Published: The Japanese Society of Internal Medicine 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109573/
id pubmed-5109573
recordtype oai_dc
spelling pubmed-51095732016-11-17 The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma Hashimoto, Shigeo Kuroha, Takashi Yano, Toshio Sato, Naoko Furukawa, Tatsuo Case Report Five cases were treated by adding daily low-dose thalidomide (50 mg) to bortezomib and dexamethasone therapy for refractory multiple myeloma. This therapy was effective in four cases, with an improvement of bone pain and regression of M-protein. One case was treated with cyclophosphamide, thalidomide, and dexamethasone, adding bortezomib after starting the three-drug combination therapy. This patient has remained in a stable disease state since the beginning of this therapy. Regarding the other four cases, a partial response and a prolonged survival for approximately one year were noted. Peripheral neuropathy did not increase after thalidomide addition. Adding low-dose thalidomide may safely improve the responses for multiple myeloma refractory to bortezomib and dexamethasone. The Japanese Society of Internal Medicine 2016-10-15 /pmc/articles/PMC5109573/ /pubmed/27746443 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Hashimoto, Shigeo
Kuroha, Takashi
Yano, Toshio
Sato, Naoko
Furukawa, Tatsuo
spellingShingle Hashimoto, Shigeo
Kuroha, Takashi
Yano, Toshio
Sato, Naoko
Furukawa, Tatsuo
The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
author_facet Hashimoto, Shigeo
Kuroha, Takashi
Yano, Toshio
Sato, Naoko
Furukawa, Tatsuo
author_sort Hashimoto, Shigeo
title The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
title_short The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
title_full The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
title_fullStr The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
title_full_unstemmed The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
title_sort addition of low-dose thalidomide to bortezomib and dexamethasone for refractory multiple myeloma
description Five cases were treated by adding daily low-dose thalidomide (50 mg) to bortezomib and dexamethasone therapy for refractory multiple myeloma. This therapy was effective in four cases, with an improvement of bone pain and regression of M-protein. One case was treated with cyclophosphamide, thalidomide, and dexamethasone, adding bortezomib after starting the three-drug combination therapy. This patient has remained in a stable disease state since the beginning of this therapy. Regarding the other four cases, a partial response and a prolonged survival for approximately one year were noted. Peripheral neuropathy did not increase after thalidomide addition. Adding low-dose thalidomide may safely improve the responses for multiple myeloma refractory to bortezomib and dexamethasone.
publisher The Japanese Society of Internal Medicine
publishDate 2016
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109573/
_version_ 1613727392383107072

Similar Items